UCB makes case for wider Bimzelx label in USA

Belgium’s largest pharma company, UCB (Euronext: UCB), has announced new long-term data from the Bimzelx (bimekizumab) Phase IIb study BE AGILE and its open label extension (OLE).

Patients with ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis, treated with the interleukin (IL)-17A and IL-17F inhibitor, showed sustained improvements in signs and symptoms, disease activity, physical function and health-related quality of life for up to five years, with a consistent safety profile through five years of treatment.

"There is a need for additional treatment options for people living with AS since many people do not achieve long-term disease control"Bimzelx is not approved in the USA for the treatment of AS, though it did l ast month gain approval for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.